The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome
- Conditions
- Velocardiofacial syndrome (VCFS)DiGeorge syndrome100836241004225810039628
- Registration Number
- NL-OMON52172
- Lead Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 46
• Confirmed diagnosis of 22q11.2 deletion syndrome established by FISH,
microarray or MLPA
analysis.
• 16 year or older of age and mentally competent (determined by an experienced
physician) to
decide about participation and give informed consent.
• 16 years, incompetent to provide written informed consent. In these cases
consent will be
obtained from the legal representative of the subject.
• Presence of psychotic and/or cognitive symptoms (defined as a score of >=4,
moderately ill, on the
Clinical Global Impression-Schizophrenia Scale (CGI-SCH)).
• Other chromosomal abnormalities.
• Current substance abuse / dependence.
• Use of psychotropic medication and / or first-generation antipsychotics or
clozapine, with the
exception of second-generation antipsychotics.
• Contraindications for MRI.
• Pre-existing liver function disorders and / or ALAT/ASAT > 3x ULN.
• Contraindications for riluzole.
• Pregnancy, or trying to get pregnant and breastfeeding.
• In case of mentally incompetent patients, resistance to participation will be
an additional exclusion
criterion.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary study endpoint will be the change in glutamate and GABA<br /><br>concentrations in the anterior cingulate cortex.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary endpoint will be the change in psychotic and cognitive symptom<br /><br>severity. </p><br>